Continuous Glucose Monitoring MarketSize, Share & Industry Analysis, 2026-2034By ComponentBy Product TypeBy Sensor Wear DurationBy Sensing TechnologyBy ApplicationBy Age GroupBy Connectivity and IntegrationBy End UserBy Distribution ChannelBy Reimbursement Status
Full title & scope — all 10 axes with their segments
Continuous Glucose Monitoring Market Size, Share & Industry Analysis, By Component (Sensors, Transmitters, Receivers and Readers, Software and Data Platforms, Insertion and Accessories), By Product Type (Real-Time CGM, Intermittently Scanned CGM, Professional CGM, Over-the-Counter CGM), By Sensor Wear Duration (Up to 7 Days, 8 to 10 Days, 11 to 15 Days, Beyond 15 Days), By Sensing Technology (Minimally Invasive Enzymatic Electrochemical, Implantable Fluorescence-Based, Non-Invasive, Microneedle-Based), By Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Prediabetes and Metabolic Health, Hospital Glycemic Management), By Age Group (Pediatric, Adult, Geriatric), By Connectivity and Integration (Standalone CGM, Integrated with Insulin Pumps, Integrated with Smart Pens, Open-Source and Third-Party Integrated), By End User (Home Care Settings, Hospitals, Clinics and Endocrinology Centers, Ambulatory Surgical and Long-Term Care Facilities, Research and Clinical Trial Organizations), By Distribution Channel (Retail Pharmacies, Online Pharmacies and E-Commerce, Direct-to-Consumer / Manufacturer Direct, Durable Medical Equipment Suppliers, Hospital Pharmacies), By Reimbursement Status (Public Insurance Reimbursed, Private Insurance Reimbursed, Out-of-Pocket), and Regional Forecast, 2026-2034
Market outlook, key takeaways, drivers and challenges for the report period.
- 01By ComponentSensors · Transmitters · Receivers and Readers
- 02By Product TypeReal-Time CGM · Intermittently Scanned CGM · Professional CGM
- 03By Sensor Wear DurationUp to 7 Days · 8 to 10 Days · 11 to 15 Days
- 04By Sensing TechnologyMinimally Invasive Enzymatic Electrochemical · Implantable Fluorescence-Based · Non-Invasive
- 05By ApplicationType 1 Diabetes · Type 2 Diabetes · Gestational Diabetes
- 06By Age GroupPediatric · Adult · Geriatric
- 07By Connectivity and IntegrationStandalone CGM · Integrated with Insulin Pumps · Integrated with Smart Pens
- 08By End UserHome Care Settings · Hospitals · Clinics and Endocrinology Centers
- 09By Distribution ChannelRetail Pharmacies · Online Pharmacies and E-Commerce · Direct-to-Consumer / Manufacturer Direct
- 10By Reimbursement StatusPublic Insurance Reimbursed · Private Insurance Reimbursed · Out-of-Pocket
- 11By Region
Market Analysis & Outlook
Continuous glucose monitoring systems measure glucose in interstitial fluid at frequent intervals through the day, using a wearable sensor, a transmitter and a display on a receiver, phone or insulin pump. The category covers sensors, transmitters, readers, software and insertion accessories, sold as real-time, intermittently scanned, professional and over-the-counter products. Buyers are people with diabetes or at risk of it, hospitals, clinics and diabetes centers, and the pharmacies and suppliers that serve them.
The global continuous glucose monitoring market stood at USD 12.8 billion in 2025. A forecast-period rate of 11.47% takes it to USD 36 billion by 2034, and the study reports every year in between, passing USD 4.3 billion in 2020, USD 10.7 billion in 2024, USD 15.1 billion in 2026 and USD 23.9 billion in 2030.
On the component axis, growth rates run from 5.7% for Receivers and Readers up to 17.8% for Software and Data Platforms. Sensors carries the volume: USD 6.656 billion and 52% of revenue in 2025, USD 18 billion and 50% in 2034. Share moves toward Software and Data Platforms and away from Sensors, Transmitters, Receivers and Readers and Insertion and Accessories, though no line shrinks in revenue terms.
The product type split puts Real-Time CGM (rtCGM) first, at USD 8.704 billion and 68% of revenue in 2025, rising to USD 25.2 billion and 70% in 2034. Over-the-Counter CGM grows faster at 24.6% against 12.5%, moving from 7% of revenue to 18% by 2034. It cuts the same total as the component axis from a different commercial angle, so revenue does not add across the two.
North America is the largest region at 45% of 2025 revenue, worth USD 5.76 billion and reaching USD 14.04 billion by 2034. Europe follows at 24%, moving from USD 3.072 billion to USD 8.28 billion, and Middle East and Africa is the smallest at 4.5%. Asia Pacific gain share across the period, so growth is not distributed evenly between regions.
Coverage extends to five regions, five component lines and ten segmentation axes over the full fifteen years. The 2025 total itself is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- A forecast-period rate of 11.47% takes the market from USD 12.8 billion in 2025 to USD 36 billion in 2034, against 24.37% recorded over the 2020-2025 historical period.
- 52% of 2025 revenue sits in Sensors (USD 6.656 billion) and it remains the largest component line in 2034 at USD 18 billion and 50%.
- At 17.8%, Software and Data Platforms grows faster than any other component line, moving from USD 1.536 billion and 12% of revenue in 2025 to USD 7.2 billion and 20% in 2034.
- Against a base case of USD 36 billion in 2034, the study also reports a bear case at USD 26 billion and a bull case at USD 41 billion, with the assumptions behind each set out separately.
- The largest region is North America, generating USD 5.76 billion in 2025 (45% of the global total) and USD 14.04 billion by 2034, ahead of Europe at 24%.
- Within North America, the United States is the worked country example, at USD 5.1 billion in 2025; 88.54% of regional revenue in the base year, and USD 12.4 billion by 2034.
- Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.
Market Trends
Revenue Share, By Component
Base year 2025Sensors leads with 52.0% of component segment revenue.
Share of component segment revenue, most recent base year.
Three things move over 2026-2034, and they are worth separating: the component mix, the regional balance, and the 11.47% compounding underneath both.
All three are changes in mix, not in direction: nothing contracts, and the movement is in which lines and regions absorb the new revenue.
Software and Data Platforms outpaces Receivers and Readers. The widest spread on the component axis is between Software and Data Platforms at 17.8% and Receivers and Readers at 5.7%. By 2034 the two sit at 20% and 5% of revenue, against 12% and 8% in 2025. Neither contracts: USD 1.536 billion becomes USD 7.2 billion, USD 1.024 billion becomes USD 1.8 billion. What the spread decides is which of them a supplier's revenue is exposed to.
Asia Pacific gain regional share. Asia Pacific moves from 22% of revenue in 2025 to 30% in 2034, worth USD 2.816 billion rising to USD 10.8 billion. The offsetting side is North America at 45% moving to 39%, Europe at 24% moving to 23%, Latin America at 4.5% moving to 4%, Middle East and Africa at 4.5% moving to 4%, none of which contracts. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.
A continuation, not an inflection. The market moves through USD 4.3 billion in 2020, USD 10.7 billion in 2024, USD 12.8 billion in 2025, USD 15.1 billion in 2026, USD 23.9 billion in 2030 and USD 36 billion in 2034. No year breaks the trajectory, and the 11.47% forecast rate compares with 24.37% recorded over 2020-2025, a continuation, not an inflection. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the component and regional mixes matter more to a forecast than the headline rate does.
Market Growth Factors
Software and Data Platforms carries the market's growth rate
Market Drivers
3- 01Software and Data Platforms carries the market's growth rate
Software and Data Platforms compounds at 17.8% against 11.47% for the market, rising from USD 1.536 billion in 2025 to USD 7.2 billion in 2034 and from 12% of revenue to 20%. Set against 5.7% at the other end of the axis, this is the line that decides whether the market's 11.47% holds. That makes position on the component axis a growth decision, not a product one.
- 02North America carries 45% of the base and keeps growing
North America is the largest region at USD 5.76 billion in 2025, 45% of global revenue, and reaches USD 14.04 billion by 2034 while holding 39%. Europe adds a further 24% at USD 3.072 billion, reaching USD 8.28 billion. Together the two account for the majority of both the 2025 base and the revenue added by 2034, which is why a regional plan treating all five regions at equal weight misreads where the growth actually lands.
- 03The trend is already in the record
USD 4.3 billion in 2020, USD 10.7 billion in 2024 and USD 12.8 billion in 2025: 24.37% compound growth before the forecast period even begins. The forecast continues at 11.47% to USD 36 billion in 2034. Fifteen years of unbroken growth in the series means the forecast rests on a demonstrated trajectory, not a projected turnaround, and it is why the 11.47% rate is applied flat across the whole period instead of ramped through it.
Growth drivers
| # | Growth driver | Impact | Gross contribution (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Wider reimbursement for Type 2 diabetes and basal insulin users | High | +8.4 | High | High | Medium |
| 2 | Integration with automated insulin delivery and connected pens | Medium-High | +6.8 | High | Medium | Medium |
| 3 | Longer-wear sensors and falling cost per day of use | Medium-High | +5.2 | Medium | High | Medium |
| 4 | Over-the-counter and metabolic health adoption | Medium | +4 | Low | Medium | High |
| 5 | Others | Low | +2.8 | Low | Low | Low |
| Total | +27.2 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Pricing pressure and reimbursement limits in tenders and public programs | Medium-High | −2.2 | Medium | High | High |
| 2 | Accuracy concerns, skin reactions and sensor supply interruptions | Medium | −1.2 | Medium | Medium | Low |
| 3 | Data privacy and regulatory compliance burden | Low | −0.6 | Low | Medium | Medium |
| Total | −4 | |||||
Drivers contribute 27.2 USD Billion and restraints remove 4 USD Billion, a net 23.2 USD Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Growth in the global continuous glucose monitoring market comes from three measurable sources over 2026-2034: the market's own compounding at 11.47%, the share gained by faster-growing component lines, and expansion in the regions taking a larger part of global revenue.
Restraining Factors
What holds the forecast back
Market Restraints
2- 01What holds the forecast back
A bear case of USD 26 billion in 2034, against USD 36 billion in the base case, rests on one stated assumption: coverage expansion stalls, tender pricing cuts net price per sensor faster than volume grows, and a sensor safety action or supply interruption slows adoption in the largest markets. Neither case changes the USD 12.8 billion 2025 base.
- 02Sensors holds the blended rate down
Sensors carries 52% of 2025 revenue at USD 6.656 billion but compounds at 11% against 11.47% for the market, taking its share to 50% by 2034 even as revenue rises to USD 18 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
Large public and private payers extend coverage to most people with Type 2 diabetes, over-the-counter sales grow quickly, and longer-wear sensors lower cost per day enough to widen use in lower-income markets. On that assumption the market reaches USD 41 billion by 2034 against USD 36 billion in the base case, from the same USD 12.8 billion in 2025.
- 02Software and Data Platforms share moves from 12% to 20%
Software and Data Platforms grows at 17.8% against 11.47% for the market, adding revenue from USD 1.536 billion in 2025 to USD 7.2 billion in 2034 and taking its share from 12% to 20%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Sensors.
Market Challenges
One component line carries the market
Market Challenges
2- 01One component line carries the market
With 52% of 2025 revenue and 50% of 2034 revenue (USD 6.656 billion rising to USD 18 billion) Sensors is where the market's exposure sits. That concentration means the market's own forecast is, to a large extent, a forecast for one component line.
- 02The United States is 88.54% of North America
88.54% of the leading region is one country: the United States, at USD 5.1 billion against North America's USD 5.76 billion in 2025, and USD 12.4 billion by 2034. Read as a region it looks diversified; read by weight it is not, and the regional forecast inherits whatever happens in that one market.
Segmentation Analysis
10 axesten segmentation axes are reported; by component, by product type, sensor wear duration, sensing technology, application, age group, connectivity and integration, end user, distribution channel and reimbursement status. Each axis cuts the same total revenue along a different commercial dimension, so the splits are alternative views of one market, not additions to it.
There are five lines on the component axis, and all of them grow in revenue between 2025 and 2034. What separates them is share: one gains it, the rest give it up.
By Component · 5 segments
Sensors Led by Component in 2025, with Software and Data Platforms Growing Fastest
- Largest Sensors · 52%
- Fastest Software and Data Platforms · 17.8%
- Moves most Software and Data Platforms · +8 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Sensors | $6.66B | 52% | $18B | 50%-2 | 11% |
| Transmitters | $1.54B | 12% | $3.24B | 9%-3 | 7.9% |
| Receivers and Readers | $1.02B | 8% | $1.80B | 5%-3 | 5.7% |
| Software and Data Platforms | $1.54B | 12% | $7.20B | 20%+8 | 17.8% |
| Insertion and Accessories | $2.05B | 16% | $5.76B | 16% | 11.5% |
Sensors lead because they are the single-use part replaced every wear cycle, so each user generates recurring revenue for the supplier. Software and data platforms grow fastest as clinics, payers and insulin delivery systems depend more on shared glucose data, and as analytics and subscription services are added on top of the installed hardware base. The order does not change: Sensors is still largest in 2034, and what moves is how much it holds. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Product Type · 4 segments
Over-the-Counter CGM Outpaces the Axis While Real-Time CGM (rtCGM) Holds the Largest Share
- Largest Real-Time CGM (rtCGM) · 68%
- Fastest Over-the-Counter CGM · 24.6%
- Moves most Intermittently Scanned CGM (isCGM / Flash) · -12 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Real-Time CGM (rtCGM) | $8.70B | 68% | $25.20B | 70%+2 | 12.5% |
| Intermittently Scanned CGM (isCGM / Flash) | $2.56B | 20% | $2.88B | 8%-12 | 1.3% |
| Professional CGM | $0.64B | 5% | $1.44B | 4%-1 | 9.4% |
| Over-the-Counter CGM | $0.90B | 7% | $6.48B | 18%+11 | 24.6% |
Real-time systems lead because they alert users to highs and lows and connect to insulin delivery, which payers increasingly cover. Over-the-counter products grow fastest as sensors reach people who do not use insulin and can be bought without a prescription through pharmacies and online channels, widening the buyer base beyond clinically managed patients. The order does not change: Real-Time CGM (rtCGM) is still largest in 2034, and what moves is how much it holds.
By Sensor Wear Duration · 4 segments
Scale in 8 to 10 Days and Growth in Beyond 15 Days Define the Sensor wear duration Axis
- Largest 8 to 10 Days · 42%
- Fastest Beyond 15 Days · 26.7%
- Moves most 11 to 15 Days · +14 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Up to 7 Days | $2.56B | 20% | $2.88B | 8%-12 | 1.3% |
| 8 to 10 Days | $5.38B | 42% | $10.80B | 30%-12 | 8.1% |
| 11 to 15 Days | $4.22B | 33% | $16.92B | 47%+14 | 16.7% |
| Beyond 15 Days | $0.64B | 5% | $5.40B | 15%+10 | 26.7% |
The mid-length wear bands lead because most installed users are on them today. The longest-wear band grows fastest as longer-lasting sensors reduce insertion burden and cost per day of wear, and as new clearances move users up from shorter formats, with the shortest band losing share as it is replaced. Leadership changes hands: 11 to 15 Days is the largest line by 2034, not 8 to 10 Days.
By Sensing Technology · 4 segments
Minimally Invasive Enzymatic Electrochemical Led by Sensing technology in 2025, with Non-Invasive Growing Fastest
- Largest Minimally Invasive Enzymatic Electrochemical · 90.5%
- Fastest Non-Invasive · 36.9%
- Moves most Minimally Invasive Enzymatic Electrochemical · -12.5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Minimally Invasive Enzymatic Electrochemical | $11.58B | 90.5% | $28.08B | 78%-12.5 | 10.3% |
| Implantable Fluorescence-Based | $0.83B | 6.5% | $3.24B | 9%+2.5 | 16.3% |
| Non-Invasive | $0.13B | 1% | $2.16B | 6%+5 | 36.9% |
| Microneedle-Based | $0.26B | 2% | $2.52B | 7%+5 | 28.9% |
Minimally invasive enzymatic electrochemical sensing leads because it is the proven, cleared and reimbursed technology that nearly every installed system uses. Non-invasive sensing grows fastest from a very small base, because consumer wearable interest and early development programs create room for new entrants once accuracy against reference methods is shown. By 2034 Minimally Invasive Enzymatic Electrochemical is still ahead, making this a shift in weight, not a change of leader.
By Application · 5 segments
Type 1 Diabetes Led by Application in 2025, with Prediabetes and Metabolic Health Growing Fastest
- Largest Type 1 Diabetes · 58%
- Fastest Prediabetes and Metabolic Health · 26.7%
- Moves most Type 1 Diabetes · -18 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Type 1 Diabetes | $7.42B | 58% | $14.40B | 40%-18 | 7.6% |
| Type 2 Diabetes | $4.22B | 33% | $15.48B | 43%+10 | 15.5% |
| Gestational Diabetes | $0.26B | 2% | $1.08B | 3%+1 | 17.3% |
| Prediabetes and Metabolic Health | $0.38B | 3% | $3.24B | 9%+6 | 26.7% |
| Hospital Glycemic Management | $0.51B | 4% | $1.80B | 5%+1 | 15% |
Type 1 diabetes leads because continuous monitoring is already standard care and well reimbursed for this group. Prediabetes and metabolic health grows fastest as wellness and prevention buyers adopt sensors, while Type 2 diabetes becomes the largest line over the forecast as coverage extends to people on basal insulin and other therapies. Leadership changes hands: Type 2 Diabetes is the largest line by 2034, not Type 1 Diabetes.
By Age Group · 3 segments
By Age Group
- Largest Adult (18 to 64 Years) · 63%
- Fastest Geriatric (65 Years and Above) · 13.9%
- Moves most Geriatric (65 Years and Above) · +3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pediatric (0 to 17 Years) | $2.18B | 17% | $5.40B | 15%-2 | 10.6% |
| Adult (18 to 64 Years) | $8.06B | 63% | $22.32B | 62%-1 | 12% |
| Geriatric (65 Years and Above) | $2.56B | 20% | $8.28B | 23%+3 | 13.9% |
Scale in Adult (18 to 64 Years) and Growth in Geriatric (65 Years and Above) Define the Age group Axis Adults lead because they form most of the people living with diabetes and have the highest sensor usage. Geriatric users grow fastest as coverage widens, caregivers seek remote alerts, and older adults on insulin move from fingerstick testing to continuous monitoring, while pediatric use is already well established. The order does not change: Adult (18 to 64 Years) is still largest in 2034, and what moves is how much it holds.
By Connectivity and Integration · 4 segments
Standalone CGM Led by Connectivity and integration in 2025, with Integrated with Smart Pens Growing Fastest
- Largest Standalone CGM · 52%
- Fastest Integrated with Smart Pens · 17.8%
- Moves most Standalone CGM · -14 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Standalone CGM | $6.66B | 52% | $13.68B | 38%-14 | 8.3% |
| Integrated with Insulin Pumps | $4.61B | 36% | $15.84B | 44%+8 | 14.7% |
| Integrated with Smart Pens | $1.15B | 9% | $5.04B | 14%+5 | 17.8% |
| Open-Source and Third-Party Integrated | $0.38B | 3% | $1.44B | 4%+1 | 15.8% |
Standalone systems lead because many users start with a sensor and a phone app before adding insulin delivery. Smart pen integration grows fastest as connected pens bring glucose data to people on multiple daily injections, and pump integration gains share as automated insulin delivery spreads and ties a sensor to every pump user. Leadership changes hands: Integrated with Insulin Pumps is the largest line by 2034, not Standalone CGM.
By End User · 5 segments
Home Care Settings Holds the Largest End user Share and Is Still the Quickest to Grow
- Largest Home Care Settings · 72%
- Fastest Home Care Settings · 12.9%
- Moves most Home Care Settings · +4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Home Care Settings | $9.22B | 72% | $27.36B | 76%+4 | 12.9% |
| Hospitals | $1.41B | 11% | $3.24B | 9%-2 | 9.7% |
| Clinics and Endocrinology Centers | $1.41B | 11% | $3.24B | 9%-2 | 9.7% |
| Ambulatory Surgical and Long-Term Care Facilities | $0.51B | 4% | $1.44B | 4% | 12.2% |
| Research and Clinical Trial Organizations | $0.26B | 2% | $0.72B | 2% | 12.2% |
Home care settings lead because continuous monitoring is worn and managed by the patient between visits, not inside a facility. Home care also grows fastest, as pharmacy dispensing and remote data sharing reduce the need for clinic-based monitoring, while hospital use grows more slowly from a smaller base. Home Care Settings remains the largest line through 2034, so the axis changes in proportion, not in order.
By Distribution Channel · 5 segments
Retail Pharmacies Held the Dominant Share of the Distribution channel Segment in 2025
- Largest Retail Pharmacies · 38%
- Fastest Online Pharmacies and E-Commerce · 18%
- Moves most Retail Pharmacies · -8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Retail Pharmacies | $4.86B | 38% | $10.80B | 30%-8 | 9.3% |
| Online Pharmacies and E-Commerce | $1.79B | 14% | $7.92B | 22%+8 | 18% |
| Direct-to-Consumer / Manufacturer Direct | $1.54B | 12% | $6.12B | 17%+5 | 16.6% |
| Durable Medical Equipment Suppliers | $3.58B | 28% | $8.64B | 24%-4 | 10.3% |
| Hospital Pharmacies | $1.02B | 8% | $2.52B | 7%-1 | 10.5% |
Retail pharmacies lead because most sensors are dispensed against a prescription across the counter, backed by established payer billing. Online pharmacies and e-commerce grow fastest as home delivery, automatic refills and over-the-counter sales move repeat purchases away from physical stores, and manufacturer direct sales follow the same pattern. Retail Pharmacies remains the largest line through 2034, so the axis changes in proportion, not in order.
By Reimbursement Status · 3 segments
Public Insurance Reimbursed Outpaces the Axis While Private Insurance Reimbursed Holds the Largest Share
- Largest Private Insurance Reimbursed · 44%
- Fastest Public Insurance Reimbursed · 13.7%
- Moves most Public Insurance Reimbursed · +4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Public Insurance Reimbursed | $3.84B | 30% | $12.24B | 34%+4 | 13.7% |
| Private Insurance Reimbursed | $5.63B | 44% | $15.84B | 44% | 12.2% |
| Out-of-Pocket | $3.33B | 26% | $7.92B | 22%-4 | 10.1% |
Private insurance reimbursed leads because commercial plans cover the largest group of users in the biggest markets. Public insurance grows fastest as national and government programs extend coverage to more patient groups, especially people with Type 2 diabetes, while out-of-pocket purchases lose share as coverage replaces self-payment. By 2034 Private Insurance Reimbursed is still ahead, making this a shift in weight, not a change of leader.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 6 points of share move elsewhere by 2034, while revenue still grows 2.4×.
- Rank 1 of 5
- 2025 share 45%
- By 2034 39%
- Revenue $5.76B → $14.04B
USD 5.76 billion of 2025 revenue is generated in North America, 45% of the global continuous glucose monitoring market on the way to USD 14.04 billion by 2034. Among the five regions it ranks first by revenue in both years.
By 2034 the share stands at 39%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Sensors leads here as it does globally, at 52% of 2025 revenue, and Software and Data Platforms again grows fastest at 17.8%. North America is reported axis by axis and country by country in the full study.
United States
Sets the pace for North America at 88.5% of it, growing 2.4×.
- In region 1 of 2
- Of region 88.5%
- Of global 39.8%
- Revenue $5.10B → $12.40B
USD 5.1 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 12.4 billion by 2034. Carrying 88.54% of the region in the base year, it sets North America's direction instead of merely contributing to it. Against regional totals of USD 5.76 billion in 2025 and USD 14.04 billion in 2034, it is the country the full report breaks out in detail.
the United States buys along the same lines as the market globally; Sensors first at 52% of 2025 revenue and 50% in 2034, Software and Data Platforms fastest at 17.8% on a share moving from 12% to 20%. Its 88.54% weight in North America means those movements carry straight into the regional totals. Revenue by component for the United States is reported separately in the full report.
In the United States, continuous glucose monitoring systems are regulated as medical devices by the Food and Drug Administration, acting through its Center for Devices and Radiological Health. Systems intended for treatment decisions are generally classified as moderate risk and reach the market through a premarket notification or a De Novo request, with integrated systems that drive insulin delivery handled under the same device framework. Suppliers must register their establishments, list their devices, operate a quality management system under the Quality System Regulation, report adverse events and follow unique device identification and labelling rules. Software and cybersecurity expectations form part of the premarket review.
The suppliers tracked in this study (Dexcom, Inc., Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd, Senseonics Holdings, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, LifeScan, Inc., Sinocare Inc., Medtrum Technologies Inc., Roche Diabetes Care GmbH, i-SENS, Inc., Glucotrack, Inc., Biolinq, Inc., Embecta Corp., Terumo Corporation, Yuwell Medical (Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.), Microtech Medical (Hangzhou) Co., Ltd., Ypsomed Holding AG, Diabeloop SA, Trividia Health, Inc., Nemaura Medical Inc., Dexcom Europe / Eversense partner Ascensia, Meiqi / Shenzhen Silicon Biotech Co., Ltd., Glucomen / A. Menarini Diagnostics S.r.l. and Sibionics (Shenzhen Sibionics Technology Co., Ltd.)) compete in the United States across the component lines above. Volume sits in Sensors at 52% of 2025 revenue; movement sits in Software and Data Platforms at 17.8% growth. Country-level shares and positioning per company sit in the full report.
Canada
2nd-largest in North America, growing 2.5×.
- In region 2 of 2
- Of region 6.9%
- Of global 3.1%
- Revenue $0.40B → $1B
Within North America, Canada accounts for 6.94% of regional revenue and 3.13% of the global total, worth USD 0.4 billion in 2025 and USD 1 billion by 2034.
Europe Market Analysis
The 2nd-largest region covered — 1 point of share move elsewhere by 2034, while revenue still grows 2.7×.
- Rank 2 of 5
- 2025 share 24%
- By 2034 23%
- Revenue $3.07B → $8.28B
USD 3.072 billion of 2025 revenue is generated in Europe, 24% of the global continuous glucose monitoring market with USD 8.28 billion projected for 2034. Among the five regions it ranks second by revenue in both years.
By 2034 the share stands at 23%, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Sensors leads here as it does globally, at 52% of 2025 revenue, and Software and Data Platforms again grows fastest at 17.8%. Europe is reported axis by axis and country by country in the full study.
Germany
The largest market in Europe, growing 2.5×.
- In region 1 of 3
- Of region 26%
- Of global 6.3%
- Revenue $0.80B → $2B
Germany is the largest market within Europe, generating USD 0.8 billion in 2025 and projected to reach USD 2 billion by 2034. Its 26.04% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Against regional totals of USD 3.072 billion in 2025 and USD 8.28 billion in 2034, it is the country the full report breaks out in detail.
Germany buys along the same lines as the market globally; Sensors first at 52% of 2025 revenue and 50% in 2034, Software and Data Platforms fastest at 17.8% on a share moving from 12% to 20%. Since 26.04% of Europe's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-component revenue for Germany appears on its own in the full report.
In Germany, continuous glucose monitors fall under the European Union Medical Device Regulation, applied nationally through the German medical devices law. Manufacturers assign a risk class, normally the higher end of the moderate range for glucose monitoring, and obtain conformity assessment from a notified body before affixing the CE mark. Requirements cover clinical evaluation, technical documentation, a quality management system, post-market surveillance and unique device identification. Labelling must be available in German. The Federal Institute for Drugs and Medical Devices oversees vigilance reporting, while state authorities supervise the market, and reimbursement decisions sit separately with the statutory health insurance system.
Competition in Germany runs between the suppliers this study tracks: Dexcom, Inc., Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd, Senseonics Holdings, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, LifeScan, Inc., Sinocare Inc., Medtrum Technologies Inc., Roche Diabetes Care GmbH, i-SENS, Inc., Glucotrack, Inc., Biolinq, Inc., Embecta Corp., Terumo Corporation, Yuwell Medical (Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.), Microtech Medical (Hangzhou) Co., Ltd., Ypsomed Holding AG, Diabeloop SA, Trividia Health, Inc., Nemaura Medical Inc., Dexcom Europe / Eversense partner Ascensia, Meiqi / Shenzhen Silicon Biotech Co., Ltd., Glucomen / A. Menarini Diagnostics S.r.l. and Sibionics (Shenzhen Sibionics Technology Co., Ltd.). Volume sits in Sensors at 52% of 2025 revenue; movement sits in Software and Data Platforms at 17.8% growth. The commercial size of that position is USD 3.072 billion in 2025, moving to USD 8.28 billion by 2034 across the forecast period.
United Kingdom
2nd-largest in Europe, growing 2.7×.
- In region 2 of 3
- Of region 17.9%
- Of global 4.3%
- Revenue $0.55B → $1.50B
Within Europe, the United Kingdom accounts for 17.9% of regional revenue and 4.3% of the global total, worth USD 0.55 billion in 2025 and USD 1.5 billion by 2034.
France
3rd-largest in Europe, growing 2.7×.
- In region 3 of 3
- Of region 13.7%
- Of global 3.3%
- Revenue $0.42B → $1.15B
France is sized at USD 0.42 billion in 2025, rising to USD 1.15 billion by 2034; 3.28% of global revenue and 13.67% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 8 points of share by 2034, while revenue still grows 3.8×.
- Rank 3 of 5
- 2025 share 22%
- By 2034 30%
- Revenue $2.82B → $10.80B
USD 2.816 billion of 2025 revenue is generated in Asia Pacific, 22% of the global continuous glucose monitoring market rising to USD 10.8 billion in 2034. It is a leading region on this axis, third by revenue throughout the period.
30% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 11.47%; the revenue added here is disproportionate to where the region started.
The component mix reported at global level applies here, with Sensors the largest line at 52% of 2025 revenue and Software and Data Platforms the fastest-growing at 17.8%. The full report breaks Asia Pacific out along every axis and by country.
Japan
The largest market in Asia Pacific, growing 2.8×.
- In region 1 of 3
- Of region 26.6%
- Of global 5.9%
- Revenue $0.75B → $2.10B
Japan is the largest market within Asia Pacific, generating USD 0.75 billion in 2025 and projected to reach USD 2.1 billion by 2034. At 26.63% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Regional revenue of USD 2.816 billion in 2025 and USD 10.8 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Composition here matches the global split: the largest line is Sensors at 52% of 2025 revenue, easing to 50% by 2034, and the fastest is Software and Data Platforms at 17.8%, from 12% to 20%. Because the country carries 26.63% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Japan carries its own component breakdown in the full report.
In Japan, continuous glucose monitoring systems are regulated under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, administered by the Ministry of Health, Labour and Welfare with review by the Pharmaceuticals and Medical Devices Agency. Devices are placed in a risk class, and higher classes require marketing approval, often supported by registered certification bodies for those with established standards. Foreign manufacturers appoint a marketing authorisation holder in the country and must meet quality management system requirements aligned with international standards. Labelling and instructions must be in Japanese, and reimbursement is determined through a separate national insurance listing process.
In Japan the field is Dexcom, Inc., Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd, Senseonics Holdings, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, LifeScan, Inc., Sinocare Inc., Medtrum Technologies Inc., Roche Diabetes Care GmbH, i-SENS, Inc., Glucotrack, Inc., Biolinq, Inc., Embecta Corp., Terumo Corporation, Yuwell Medical (Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.), Microtech Medical (Hangzhou) Co., Ltd., Ypsomed Holding AG, Diabeloop SA, Trividia Health, Inc., Nemaura Medical Inc., Dexcom Europe / Eversense partner Ascensia, Meiqi / Shenzhen Silicon Biotech Co., Ltd., Glucomen / A. Menarini Diagnostics S.r.l. and Sibionics (Shenzhen Sibionics Technology Co., Ltd.). The commercially relevant division is 52% of 2025 revenue in Sensors, where the volume is, against 17.8% growth in Software and Data Platforms, where share moves. A supplier weighted toward Asia Pacific is competing over a base of USD 2.816 billion in 2025, reaching USD 10.8 billion by 2034 on the trajectory this study models.
China
2nd-largest in Asia Pacific, growing 5.1×.
- In region 2 of 3
- Of region 24.9%
- Of global 5.5%
- Revenue $0.70B → $3.60B
5.47% of global revenue is generated in China; USD 0.7 billion in 2025, reaching USD 3.6 billion in 2034, and 24.86% of Asia Pacific.
Australia
3rd-largest in Asia Pacific, growing 2.5×.
- In region 3 of 3
- Of region 9.9%
- Of global 2.2%
- Revenue $0.28B → $0.70B
2.19% of global revenue is generated in Australia; USD 0.28 billion in 2025, reaching USD 0.7 billion in 2034, and 9.94% of Asia Pacific.
Latin America Market Analysis
The 4th-largest region covered — 0.5 points of share move elsewhere by 2034, while revenue still grows 2.5×.
- Rank 4 of 5
- 2025 share 4.5%
- By 2034 4%
- Revenue $0.58B → $1.44B
4.5% of the global continuous glucose monitoring market sits in Latin America in 2025, worth USD 0.576 billion and reaches USD 1.44 billion by 2034. It is a marginal region on this axis, fourth by revenue throughout the period.
4% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
The component mix reported at global level applies here, with Sensors the largest line at 52% of 2025 revenue and Software and Data Platforms the fastest-growing at 17.8%. Latin America is reported axis by axis and country by country in the full study.
Brazil
The largest market in Latin America, growing 2.6×.
- In region 1 of 2
- Of region 34.7%
- Of global 1.6%
- Revenue $0.20B → $0.52B
Brazil is the largest market within Latin America, generating USD 0.2 billion in 2025 and projected to reach USD 0.52 billion by 2034. It accounts for 34.72% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 0.576 billion in 2025 and USD 1.44 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in Brazil follows the component mix reported at global level: Sensors is the largest line at 52% of 2025 revenue, moving to 50% by 2034, while Software and Data Platforms grows fastest at 17.8% and takes its share from 12% to 20%. Its 34.72% weight in Latin America means those movements carry straight into the regional totals. Brazil carries its own component breakdown in the full report.
In Brazil, the National Health Surveillance Agency, known as ANVISA, regulates continuous glucose monitors as medical devices. Products are assigned to a risk class under its device rules, and moderate to high risk classes require registration before sale, rather than a simple notification. Registration depends on technical documentation, evidence of safety and performance, and a local registration holder for foreign suppliers. Manufacturers must also hold a certificate of good manufacturing practice issued by the agency. Certain devices require conformity assessment under the national INMETRO scheme, and labelling and instructions for use must be provided in Portuguese.
Dexcom, Inc., Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd, Senseonics Holdings, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, LifeScan, Inc., Sinocare Inc., Medtrum Technologies Inc., Roche Diabetes Care GmbH, i-SENS, Inc., Glucotrack, Inc., Biolinq, Inc., Embecta Corp., Terumo Corporation, Yuwell Medical (Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.), Microtech Medical (Hangzhou) Co., Ltd., Ypsomed Holding AG, Diabeloop SA, Trividia Health, Inc., Nemaura Medical Inc., Dexcom Europe / Eversense partner Ascensia, Meiqi / Shenzhen Silicon Biotech Co., Ltd., Glucomen / A. Menarini Diagnostics S.r.l. and Sibionics (Shenzhen Sibionics Technology Co., Ltd.) are the suppliers covered in Brazil. Two different problems sit on the same axis: holding Sensors at 52% of 2025 revenue, and taking Software and Data Platforms while it grows at 17.8%. A supplier weighted toward Latin America is competing over a base of USD 0.576 billion in 2025, reaching USD 1.44 billion by 2034 on the trajectory this study models.
Mexico
2nd-largest in Latin America, growing 2.7×.
- In region 2 of 2
- Of region 19.1%
- Of global 0.9%
- Revenue $0.11B → $0.30B
0.86% of global revenue is generated in Mexico; USD 0.11 billion in 2025, reaching USD 0.3 billion in 2034, and 19.1% of Latin America.
Middle East and Africa Market Analysis
The 5th-largest region covered — 0.5 points of share move elsewhere by 2034, while revenue still grows 2.5×.
- Rank 5 of 5
- 2025 share 4.5%
- By 2034 4%
- Revenue $0.58B → $1.44B
In Middle East and Africa, 4.5% of global revenue puts 2025 at USD 0.576 billion with USD 1.44 billion projected for 2034. Among the five regions it ranks fifth by revenue in both years.
Share settles at 4% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
Within the region the component split tracks the global one; 52% of 2025 revenue in Sensors, fastest growth of 17.8% in Software and Data Platforms. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.9×.
- In region 1 of 2
- Of region 15.6%
- Of global 0.7%
- Revenue $0.09B → $0.26B
The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.09 billion in 2025 and USD 0.26 billion in 2034. At 15.63% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. The region itself runs USD 0.576 billion to USD 1.44 billion over the same period, and this is the market carrying the country-level detail in the full report.
Saudi Arabia buys along the same lines as the market globally; Sensors first at 52% of 2025 revenue and 50% in 2034, Software and Data Platforms fastest at 17.8% on a share moving from 12% to 20%. Since 15.63% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports Saudi Arabia by component separately.
In Saudi Arabia, the Saudi Food and Drug Authority regulates continuous glucose monitors as medical devices under its medical devices interim regulation. Suppliers need an authorised representative within the Kingdom, and the device must obtain a marketing authorisation based on its risk class, supported by technical documentation and evidence of approval in a recognised reference jurisdiction where applicable. Establishments must be licensed, and manufacturers are expected to operate a quality management system consistent with international standards. Labelling must carry Arabic information, and post-market surveillance and incident reporting obligations apply once the device is on the market.
Competition in Saudi Arabia runs between the suppliers this study tracks: Dexcom, Inc., Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd, Senseonics Holdings, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, LifeScan, Inc., Sinocare Inc., Medtrum Technologies Inc., Roche Diabetes Care GmbH, i-SENS, Inc., Glucotrack, Inc., Biolinq, Inc., Embecta Corp., Terumo Corporation, Yuwell Medical (Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.), Microtech Medical (Hangzhou) Co., Ltd., Ypsomed Holding AG, Diabeloop SA, Trividia Health, Inc., Nemaura Medical Inc., Dexcom Europe / Eversense partner Ascensia, Meiqi / Shenzhen Silicon Biotech Co., Ltd., Glucomen / A. Menarini Diagnostics S.r.l. and Sibionics (Shenzhen Sibionics Technology Co., Ltd.). Sensors, at 52% of 2025 revenue, is where the volume sits, and Software and Data Platforms, growing at 17.8%, is where position changes hands over the forecast period. The commercial size of that position is USD 0.576 billion in 2025 and USD 1.44 billion by 2034, 4.5% of the global total in the base year.
United Arab Emirates
2nd-largest in Middle East and Africa, growing 2.9×.
- In region 2 of 2
- Of region 12.2%
- Of global 0.6%
- Revenue $0.07B → $0.20B
Within Middle East and Africa, the United Arab Emirates accounts for 12.15% of regional revenue and 0.55% of the global total, worth USD 0.07 billion in 2025 and USD 0.2 billion by 2034.
Download a free sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Component, Product Type, Sensor Wear Duration, Sensing Technology, Application, Age Group, Connectivity and Integration, End User, Distribution Channel, Reimbursement Status, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Suppliers Compete on Sensors Volume and Software and Data Platforms Momentum
The suppliers covered are: Dexcom, Inc., Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd, Senseonics Holdings, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, LifeScan, Inc., Sinocare Inc., Medtrum Technologies Inc., Roche Diabetes Care GmbH, i-SENS, Inc., Glucotrack, Inc., Biolinq, Inc., Embecta Corp., Terumo Corporation, Yuwell Medical (Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.), Microtech Medical (Hangzhou) Co., Ltd., Ypsomed Holding AG, Diabeloop SA, Trividia Health, Inc., Nemaura Medical Inc., Dexcom Europe / Eversense partner Ascensia, Meiqi / Shenzhen Silicon Biotech Co., Ltd., Glucomen / A. Menarini Diagnostics S.r.l. and Sibionics (Shenzhen Sibionics Technology Co., Ltd.).
The component axis, not the regional one, is where competition happens. Sensors is 52% of 2025 revenue at USD 6.656 billion and still 50% in 2034, so it is where the volume sits and where an incumbent's position is hardest to move. Software and Data Platforms, compounding at 17.8% against 5.7% for Receivers and Readers, is where share changes hands over the forecast period. A supplier positioned in one is not automatically positioned in the other, so a field of this size stays viable in a market of USD 12.8 billion.
Suppliers separate on sensor accuracy and wear-time reliability, manufacturing scale for single-use sensors, and the ability to hold regulatory clearances in several regions at once. The largest players add reimbursement experience, direct payer contracting, pharmacy and durable medical equipment distribution, and software ecosystems that connect sensors with insulin delivery devices and clinic data tools. Regional and smaller suppliers compete on lower price per day, local approvals and distribution, open integration with third-party apps, and focus on a single technology such as implantable or microneedle sensing. Launch timing for new clearances and supply reliability decide share gains.
Geographic reach is the other axis of competition. North America alone accounts for 45% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; Europe adds a further 24%.
Per-company profiles, financials, share and development history are in the full report and not here.
List of Key Continuous Glucose Monitoring Market Companies Profiled
27 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Dexcom, Inc.(United States)
- Abbott Laboratories(United States)
- Medtronic plc(Ireland)
- F. Hoffmann-La Roche Ltd(Switzerland)
- Senseonics Holdings, Inc.(United States)
- Insulet Corporation(United States)
- Tandem Diabetes Care, Inc.(United States)
- Ascensia Diabetes Care Holdings AG(Switzerland)
- LifeScan, Inc.(United States)
- Sinocare Inc.(China)
- Medtrum Technologies Inc.(China)
- Roche Diabetes Care GmbH(Germany)
- i-SENS, Inc.(South Korea)
- Glucotrack, Inc.(United States)
- Biolinq, Inc.(United States)
- Embecta Corp.(United States)
- Terumo Corporation(Japan)
- Yuwell Medical (Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.)(China)
- Microtech Medical (Hangzhou) Co., Ltd.(China)
- Ypsomed Holding AG(Switzerland)
- Diabeloop SA(France)
- Trividia Health, Inc.(United States)
- Nemaura Medical Inc.(United Kingdom)
- Dexcom Europe / Eversense partner Ascensia
- Meiqi / Shenzhen Silicon Biotech Co., Ltd.(China)
- Glucomen / A. Menarini Diagnostics S.r.l.(Italy)
- Sibionics (Shenzhen Sibionics Technology Co., Ltd.)(China)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 10 axes (Component, Product Type, Sensor Wear Duration, Sensing Technology, Application, Age Group, Connectivity and Integration, End User, Distribution Channel, Reimbursement Status), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 27 key companies, and the research methodology behind every estimate.
Segmentation
10 axes + regionQuestions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Continuous Glucose Monitoring Market projected to reach?
USD 36 USD Billion by 2034, CAGR 11.47%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 45% of global revenue through 2034.
05Which segment leads the market?
Sensors is the largest line by Component, at 52% of revenue in 2025.
06Who are the key companies profiled?
Dexcom, Inc., Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd, Senseonics Holdings, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, LifeScan, Inc., Sinocare Inc., Medtrum Technologies Inc., Roche Diabetes Care GmbH, i-SENS, Inc., Glucotrack, Inc., Biolinq, Inc., Embecta Corp., Terumo Corporation, Yuwell Medical (Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.), Microtech Medical (Hangzhou) Co., Ltd., Ypsomed Holding AG, Diabeloop SA, Trividia Health, Inc., Nemaura Medical Inc., Dexcom Europe / Eversense partner Ascensia, Meiqi / Shenzhen Silicon Biotech Co., Ltd., Glucomen / A. Menarini Diagnostics S.r.l., Sibionics (Shenzhen Sibionics Technology Co., Ltd.). Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.